论文部分内容阅读
每个B细胞淋巴瘤的表面免疫球蛋白都是自己特有的(独特型),可以被免疫系统识别。作者应用B细胞淋巴瘤患者自身肿瘤所表达的免疫球蛋白皮下注射免疫患者,观察1～8年的临床结果。 41例B细胞NHL患者(Ⅱ～Ⅳ期)中32例为首次缓解,9例为非首次缓解,均接受标准化疗。化疗的同时取患者自身肿瘤细胞融合于细胞系K6H6B5中,首先用酶联免疫法鉴定出免疫球蛋白产量高的杂交瘤细胞系,然后通过免疫或基因分析的方法来证明这种免疫球
The surface immunoglobulins of each B-cell lymphoma are unique (idiotype) and can be recognized by the immune system. The authors used immunoglobulins expressed in their own tumors of patients with B-cell lymphoma to immunize patients with subcutaneous injections and observed clinical results for 1 to 8 years. Of the 41 B-cell NHL patients (stages II-IV), 32 were first relieved, and 9 were non-initial remissions. All received standard chemotherapy. At the same time as the chemotherapy, the patient’s own tumor cells were fused with the cell line K6H6B5. First, a hybridoma cell line with high immunoglobulin production was identified by enzyme-linked immunosorbent assay. The immunoglobulin was then proved by immunological or genetic analysis.